เอกสารอ้างอิง
[1]. Lexicomp, Inc. Tixagevimab and cilgavimab (United States: Authorized for use): Drug information. In:Post TW, ed.UpToDate.Waltham: UpToDate; 2017 (Accessed on August 29, 2022).
[2]. Tixagevimab and cilgavimab (Evusheld). In: In Depth Answers [database on the Internet]. Greenwood Village (CO): IBM Corporation; 2022 [cited 2022 August 30]. Available from: www.micromedexsolutions.com. Subscription required to view.
[3]. Centers for Disease Control and Prevention. (2022). Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. U.S. Department of Health and Human Services. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.
[4]. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, Hou C, Wang H, Liu J, Yang D, Xu Y, Cao Z, Gao Z. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020 July 13;24(1):422.
[5].Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near KA, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022 June 9;386(23):2188-2200.
[6]. Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, Kim K, Campos JAS, Arends RH, Brodek BH, Brooks D, Garbes P, Jimenez J, Koh GCKW, Padilla KW, Streicher K, Viani RM, Alagappan V, Pangalos MN, Esser MT; TACKLE study group. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022 June 7:S2213-2600(22)00180-1.